Develops gene therapies for Alzheimer's and Parkinson's diseases.
Jun 2026Revenue $34.5M/yrExpenses $152M/yr
No trendCash runway ≈ 11 months from Jun 2026
Figures by year
When will Voyager Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $34.5M and expenses $152M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $40.4M | $172M | −$132M |
| Dec 2024 | $80.0M | $163M | −$83.3M |
| Dec 2023 | $250M | $128M | $122M |
| Dec 2022 | $40.9M | $91.7M | −$50.8M |
| Dec 2021 | $37.4M | $111M | −$73.6M |
| Dec 2020 | $171M | $144M | $27.4M |
| Dec 2019 | $104M | $156M | −$51.7M |
| Dec 2018 | $7.62M | $98.7M | −$91.1M |
| Dec 2017 | $10.1M | $82.0M | −$71.9M |
| Dec 2016 | $14.2M | $55.5M | −$41.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.